RxDoctor Payments Data

Mary Austin

Psychiatric/Mental Health · Evansville, INNPI 1437854643

Payments from drug & device makers

$3,424in general payments, 2019–2025

Across 163 payments — averaging $21.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$671
  • Axsome Therapeutics, Inc.$424
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$242
  • E.r. Squibb & Sons, L.L.C.$242
  • Alkermes, Inc.$230
  • Otsuka America Pharmaceutical, Inc.$228
  • plus $1K from 14 others

What the payments were for

  • Food & beverage$3,424100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,424 in reported general payments places this provider in the 85th percentile of 729 psychiatric/mental health providers in Indiana.

See all psychiatric/mental health providers in Indiana

Medicare billing

Part B allowed, 2024
$136,917
Medicare patients
325
Services billed
1,925

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole101$96,511
VraylarCariprazine Hcl44$56,695
BelsomraSuvorexant88$40,620
NuedextaDextromethorphan Hbr/Quinidine14$19,395
TrintellixVortioxetine Hydrobromide15$7,678
Armodafinil12$3,427
Buspirone Hcl184$2,797
Desvenlafaxine Succinate ErDesvenlafaxine Succinate47$2,760
Aripiprazole57$2,633
Lorazepam231$2,533
Rivastigmine19$2,526
Lamotrigine ErLamotrigine12$2,250
Divalproex Sodium106$2,221
Clonazepam210$2,120
Mirtazapine62$1,454

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti$228$96,511101 claims
AbbVieVraylar$671$56,69544 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$58$7,67815 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 729 psychiatric/mental health providers in Indiana.

Other psychiatric/mental health in Evansville

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →